ALIM - Shares of Alimera Sciences Inc. (ALIM) Rise to a New 52-Week High

Shares of Alimera Sciences Inc. (NASDAQ:ALIM) traded at a new 52-week high today of $13.50. Approximately 28.5 million shares have changed hands today, as compared to an average 30-day volume of 33,000 shares.

Alimera Sciences Inc. (NASDAQ:ALIM) defies analysts with a current price ($6.00) 7.1% above its average consensus price target of $5.58.

In the past 52 weeks, Alimera Sciences Inc. share prices are bracketed by a current low of $0.00 and a high of $11.85 and is now at $6.00.

Alimera Sciences is a pharmaceutical company focused on commercializing and developing treatments that address diseases affecting the back of the eye (retina). ILUVIEN(R) is Alimera's a patented micro-implant which delivers a continuous, low dose anti-inflammatory agent to the retina for up to 3 years. A $2B global market, DME is often treated with acute therapies when the fluid in the eye returns. ILUVIEN reduces the recurrence of edema leading to stable vision, with the benefit of continuous treatment due to the product's novel drug delivery technology.

Receive IBN Spotlights - "Bite Size" Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer